Muscle Cells: Tailoring the taste of cultured meat
Although the idea of growing meat in a laboratory may seem like science fiction, over a decade has passed since the first synthetic beef burger was unveiled in 2013 (Kupferschmidt, 2013). Moreover, in June 2023, two companies – Upside Foods and GOOD Meat – were granted approval by the Food and Drug Administration (FDA) to sell ‘cultured meat’ products in the United States (Wiener-Bronner, 2023).
While producing meat in a laboratory could eventually lead to a reduction in livestock farming, which would bring benefits in terms of improved animal welfare and reduced environmental impact (Post, 2012), the process is not free from challenges. For instance, there are concerns around food safety, the high cost of production, and whether the public will accept meat that has been artificially made. Also, if the cultured meat does not taste exactly like the real deal, consumers may turn away. Moreover, cultured meat products will have to compete against other, more affordable options, such as plant-based burgers.
A compelling advantage of cultured meat is that its texture, flavor and nutritional content can be tailored during production (Broucke et al., 2023). Lab-grown meat is made by isolating cells from the tissue of a live animal or fertilized egg, and differentiating them into muscle, fat and connective tissue. By altering the composition of cells generated during this process, researchers could make lab-grown meat that is personalized to an individual’s taste. However, combining and co-culturing the different source cells needed to produce these three components is no easy task. Now, in eLife, Hen Wang and co-workers – including Tongtong Ma, Ruimin Ren and Jianqi Lv as joint first authors – report an innovative approach for customizing cultured meat using just fibroblasts from chickens (Ma et al., 2024; Figure 1).

How cultured meat can be customized to enhance flavor.
First, fibroblasts were sourced from the fertilized eggs of chickens and grown on a flat surface. The cells were then implanted into a three-dimensional scaffold made up of hydrogel (grey cylinder with white dots), where they were differentiated into muscle cells. The differentiated fibroblasts were then supplemented with insulin and fatty acids to induce the deposition of fat between the muscle cells. The fat content of meat influences how it tastes and smells: by changing the amount of insulin and fatty acids, Ma et al. were able to produce cultured meat with low (beige), medium (light brown), or high (dark brown) levels of fat content.
Image Credit: Gyuhyung Jin (CC BY 4.0).
First, the team (who are based at Shandong Agricultural University and Huazhong Agricultural University) optimized the culture conditions for the chicken fibroblasts. This included changing the composition of the medium the cells were fed, and developing a three-dimensional environment, made of a substance called hydrogel, that the fibroblasts could grow and differentiate in. Ma et al. then used a previously established protocol to activate the gene for a protein called MyoD, which induces fibroblasts to transform into muscle cells (Ren et al., 2022). Importantly, the resulting muscle cells exhibited characteristics of healthy muscle cells and were distinct from muscle cells that appear during injury.
While muscle is a fundamental component of meat, the inclusion of fat and extracellular matrix proteins is essential for enhancing flavor and texture (Fraeye et al., 2020). To stimulate the formation of fat deposits between the muscle cells, the differentiated chicken muscle cells were exposed to fatty acids and insulin. This caused the cells to produce lipid droplets, signifying that the process of fat synthesis had been initiated. Measuring the level of the lipid triglyceride revealed that the fat content of the cultured fibroblasts was comparable to that in real chicken meat, and even climbed two to three times higher when insulin levels were increased.
Ma et al. then validated that the chicken fibroblasts were also able to produce various extracellular matrix proteins found in connective tissue. This is critical for forming edible cultured meat products as the tissue surrounding muscle cells gives meat its texture and structural integrity.
The study by Ma et al. underscores the potential for modulating key components (such as muscle, fat, and extracellular matrix proteins) to produce high quality lab-grown meat that is palatable to consumers. It also demonstrates how the important components of meat can be produced from just a single source of fibroblasts, rather than mixing multiple cell types together. As this is a proof-of-concept study, many of the issues associated with producing cultured meat for a mass market still persist. These include the high cost of components such as insulin, and concerns around the use of genetically modified cells: moreover, potentially toxic chemicals are required to activate the gene for MyoD.
Nevertheless, advancements in biotechnology, coupled with the recent FDA approval for genetically modified cells in lab-grown meat production (Martins et al., 2024), signal a promising future for the cultured-meat market. In the future, genetic, chemical and physical interventions may be used to precisely design other bioactive compounds found in meat, in addition to fat and muscle (Jairath et al., 2024). It may not be long until personalized cultured meat products with finely-tuned flavors, textures, and nutrients are available for sale.
References
-
Bioactive compounds in meat: Their roles in modulating palatability and nutritional valueMeat and Muscle Biology 8:16992.https://doi.org/10.22175/mmb.16992
-
Advances and challenges in cell biology for cultured meatAnnual Review of Animal Biosciences 12:345–368.https://doi.org/10.1146/annurev-animal-021022-055132
Article and author information
Author details
Publication history
Copyright
© 2024, Jin and Bao
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,403
- views
-
- 126
- downloads
-
- 2
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cell Biology
- Neuroscience
The emergence of Aβ pathology is one of the hallmarks of Alzheimer’s disease (AD), but the mechanisms and impact of Aβ in progression of the disease is unclear. The nuclear pore complex (NPC) is a multi-protein assembly in mammalian cells that regulates movement of macromolecules across the nuclear envelope; its function is shown to undergo age-dependent decline during normal aging and is also impaired in multiple neurodegenerative disorders. Yet not much is known about the impact of Aβ on NPC function in neurons. Here, we examined NPC and nucleoporin (NUP) distribution and nucleocytoplasmic transport using a mouse model of AD (AppNL-G-F/NL-G-F) that expresses Aβ in young animals. Our studies revealed that a time-dependent accumulation of intracellular Aβ corresponded with a reduction of NPCs and NUPs in the nuclear envelope which resulted in the degradation of the permeability barrier and inefficient segregation of nucleocytoplasmic proteins, and active transport. As a result of the NPC dysfunction App KI neurons become more vulnerable to inflammation-induced necroptosis – a programmed cell death pathway where the core components are activated via phosphorylation through nucleocytoplasmic shutting. Collectively, our data implicates Aβ in progressive impairment of nuclear pore function and further confirms that the protein complex is vulnerable to disruption in various neurodegenerative diseases and is a potential therapeutic target.
-
- Cell Biology
Chronic kidney disease (CKD) and atherosclerotic heart disease, frequently associated with dyslipidemia and hypertension, represent significant health concerns. We investigated the interplay among these conditions, focusing on the role of oxidized low-density lipoprotein (oxLDL) and angiotensin II (Ang II) in renal injury via G protein αq subunit (Gq) signaling. We hypothesized that oxLDL enhances Ang II-induced Gq signaling via the AT1 (Ang II type 1 receptor)-LOX1 (lectin-like oxLDL receptor) complex. Based on CHO and renal cell model experiments, oxLDL alone did not activate Gq signaling. However, when combined with Ang II, it significantly potentiated Gq-mediated inositol phosphate 1 production and calcium influx in cells expressing both LOX-1 and AT1 but not in AT1-expressing cells. This suggests a critical synergistic interaction between oxLDL and Ang II in the AT1-LOX1 complex. Conformational studies using AT1 biosensors have indicated a unique receptor conformational change due to the oxLDL-Ang II combination. In vivo, wild-type mice fed a high-fat diet with Ang II infusion presented exacerbated renal dysfunction, whereas LOX-1 knockout mice did not, underscoring the pathophysiological relevance of the AT1-LOX1 interaction in renal damage. These findings highlight a novel mechanism of renal dysfunction in CKD driven by dyslipidemia and hypertension and suggest the therapeutic potential of AT1-LOX1 receptor complex in patients with these comorbidities.